Akebia (AKBA) Therapeutics announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the European Commission to approve XOANACYL for the treatment of concomitant elevated serum phosphorous and iron deficiency in adult patients with chronic kidney disease. Averoa, a renal-focused biopharmaceutical company, licensed the rights to develop and commercialize ferric citrate from Akebia in the European Economic Area and certain countries in Europe and the Middle East. The EC will review the CHMP recommendation, and a final decision is expected in approximately two months.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKBA:
- Akebia initiated with a Buy at Jefferies
- Akebia Therapeutics: Promising Growth Potential with Vafseo Leading the Charge
- Akebia Therapeutics Announces Public Offering Pricing
- Accenture reports Q2 beat, Apple TV+ losing $1B annually: Morning Buzz
- Morning Movers: Designer Brands jumps, Accenture falls after quarterly results
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue